Letrozole induction of ovulation in clomiphene citrate resistant polycystic ovary syndrome: responders and non-responders
|
|
- Daniela Cobb
- 7 years ago
- Views:
Transcription
1 Middle East Fertility Society Journal Vol. 9, No. 2, 2004 Copyright Middle East Fertility Society Letrozole induction of ovulation in clomiphene citrate resistant polycystic ovary syndrome: responders and non-responders Aboubakr Elnashar, M.D. Hany Fouad, M.D. Magdy Eldosoky, M.D. Naser Abelgafar, M.S. Benha University Hospital Clinic, Benha, Egypt. ABSTRACT Objective: To evaluate the efficacy of Letrozole in induction of ovulation in cases of CC-resistant PCOS and to compare between Letrozole responders and non-responders. Design: Prospective trial in infertility patients treated with CC Setting: Benha University Hospital Clinic, Egypt. Patient(s): Forty-four infertile women with anovulatory PCOS who failed to ovulate with CC. Intervention(s): Letrozole was given in a dose of 2.5 mg/day from day 3 to day 7 of the menstrual cycle. When the dominant follicle reached a diameter > 18 mm, HCG U was given and timed intercourse was advised. Main outcome measure(s): Occurrence of ovulation, endomertial thickness, cervical score & pregnancy rate Results: On the day of HCG administration, the mean number of follicles 18mm was 1.21, the mean endometrial thickness was 10.2 mm and cervical mucus score was Ovulation occurred in 24 cases (54.6%) and pregnancy in 6 cases (25%). There was no significant difference between Letrozole responders and non-responders as regards the age, period of infertility, BMI, waist circumference, LH, FS H or LH/FSH ratio. Conclusion(s): Induction of ovulation with Letrozole in CC-resistant PCOS is not dependent on age, period of infertility, BMI, waist circumference, menstrual pattern, hirsutism, LH, FSH or LH/FSH ratio. Further studies are necessary to confirm these results. Key Words: Letrozole, clomiphene citrate, PCOS, ovulation, infertility Clomiphene citrate (CC) is the traditional firstline treatment for the chronic anovulation that characterizes PCOS (1). CC is accumulated in the body with low clearance rate and long half-life (5 days). Significant plasma concentrations of the active zu isomer of CC can be detected up to 6 weeks after administration. However, 20-25% of PCOS women fail to ovulate with incremental doses of CC, in addition clinical data revealed a discrepancy between ovulation rates (75-80%) and conception rates (30-40%) during CC treatment (2). Reprint requests: Aboubakr Elnashar, M.D., 24 Gomhoria st., Mansoura, Egypt. Fax: , elnashar53@hotmail.com For these patients, there are a few limited adjunctive therapies that can be tried before moving on to gonadotropin therapy or laparoscopic ovarian drilling including; bromocriptine (in the presence of hyperpolactinemia or galactorrhea), dexamethasone (to reduce adrenal androgen production), insulin sensitizers (to treat hyperinsulinemia), oral contraceptives (for pretreatment suppression of LH), pulsatile GnRH (to preserve physiologic interactive feedback) and extended doses of CC (3). However, their usefulness is limited to specific abnormalities, as many women with CC-failure do not present with any overt signs of a treatable disorder (4). Vol. 9, No. 2, 2004 Elnashar et al. Letrozole for CC-resistant PCOS patients 157
2 Table 1. Clinical and hormonal characteristics of the patients Variable Range Mean ±SD Median 1-Age (years) ± Period of infertility (years) ± Body mass index (kg/m2) ± Waist (cm) ± Waist/Hip ratio ± Menstrual pattern: Oligomenorrhea (number) 31 (71%) Amenorrhea (number) 13 (29%) 7-Hirsutism (number) 28 (64%) 8-LH (U/ml) ± FSH (U/ml) ± LH/FSH ratio ± Mitwally and Casper had reported the novel use of the aromatase inhibitor Letrozole for inducing ovulation in anovulatory women with PCOS and for augmenting ovulation in ovulatory infertile women (1). Letrozole belongs to a new group of very potent, non-steroidal aromatase inhibitor that is rapidly absorbed from the gastrointestinal tract and excreted by the kidney. The elimination halflife of Letrozole is about 2 days (5). Our objective was to evaluate the efficacy of Letrozole in induction of ovulation in cases of CC-resistant PCOS and to compare between Letrozole responders and non-responders. MATERIALS AND METHODS Forty-four infertile women were selected from the patients attending the outpatient clinic of Benha University Hospital. All patients were diagnosed as having anovulation due to PCOS. PCOS was diagnosed when the ultrasonographic findings of PCOS (>10 cysts, 2-8mm in diameter scattered either around or through an echodense, thickened central stroma) are present plus one or more of the following: oligo/amenorrhea with positive progesterone withdrawal bleeding, hirsutism/acne, obesity, raised LH/FSH ratio >2, or raised circulating androgens (Balen, 1999). All patients had previously received CC and diagnosed as having CC-failure (failure of ovulation after 6 cycles of CC reaching the dose of 150 mg daily) (3). Our inclusion criteria:1- Age: between years. 2- Period of infertility > 2 years. 3- Serum level of FSH <12 U/L and serum prolactin level were within normal limits in the early follicular phase. Exclusion criteria were history of pelvic surgery or infertility factor other than anovulation. Hirsutism was diagnosed when the Ferriman & Gallwey score is >8 (3). A two-month washout period before the Letrozole treatment cycle was used to eliminate any post-treatment effect of CC. Patients were examined generally, abdominally and locally. Weight, height, waist and hip circumferences were measured. A transvaginal ultrasound examination was performed to exclude any pelvic pathology before treatment with Letrozole. Ultrasonography was performed using Medison Scan, Sonoace 5500 with a transvaginal transducer 6.5MHz (Medison, Korea). In all patients, Letrozole (Femara; Novartis, East Hanover, NJ) was given orally in a dose of 2.5 mg/day for 5 days starting from the third day of a spontaneous or progesterone induced menstrual bleeding (6). Ovarian follicular response was monitored by transvaginal sonography starting on the next day after finishing Letrozole and thereafter according to the growth of the follicles (usually every other day). Good response was achieved when at least one mature follicle becomes > 18 mm in diameter (Speroff et al, 1999). When the optimal follicle size was reached the endometrial thickness and cervical mucus score 158 Elnashar et al. Letrozole for CC-resistant PCOS patients MEFSJ
3 Table 2. Characteristics of the Letrozole treatment cycles in responders Variable Range Mean±SD Median Day of HCG administration ± No. of days between completion of treatment with Letrozole and follicular maturity ±1.8 6 (Letrozole-free period) On the day of HCG: -No. of follicles 18mm ± Size of follicles 18mm ± Endometrial thickness (mm) ± Cervical mucus score ± were assessed and HCG U (Pregnyl; Organon, Holland) was given intramuscular and timed intercourse was advised. Endometrial thickness was assessed according to Gonen and Casper (7). Cervical mucus score was evaluated for each responding patient at the day of HCG administration. An evaluation of the cervical mucus was calculated according to Moghissi (8). Cervical mucus score was considered good if > 10. Two days after giving HCG, the patients were assessed for ultrasonographic signs of ovulation. Clinical pregnancy was defined as the detection of at least one gestational sac on transvaginal ultrasound examination starting one week after the missed period. Results of Letrozole treatment cycles were described as means ± SD, range and median of each variable. A group t-test was used for comparing two means and Chi-Square test to compare proportion. follicular maturity (Letrozole-free period) was 6.2±1.8 days. On the day of HCG administration; the mean number of follicles> or = 18 mm was 1.21±0.86 (range, 1-2) distributed as follows; 19 patients had developed 1 follicle each and 5 patients had 2 follicles each. Letrozole was very well tolerated as no patients complained of any side effect. During Letrozole treatment, ovulation occurred in 24 cases (54.6%) and clinical pregnancy in 6 cases (25%). These pregnancies were single and resulted from timed intercourse in 6 couples; 4 of them developed one follicle each and two couples developed 2 follicles each. There were neither abortions nor multiple pregnancies. Table 3 shows the clinical characteristics of both Letrozole-responders and non-responders, there was insignificant difference between both groups as regards age, period of infertility, BMI, waist circumference, W/H ratio, LH, FSH and LH/FSH ratio. RESULTS Table 1 shows demographic, clinical and hormonal features of all women involved in this study. All patients were either overweight or obese with a mean BMI, 29.61±3.35 Kg/m2 (range ) with android obesity as indicated by waist circumference (mean 99.9±8.98 cm) and waist/hip ratio (mean= 0.98± 0.04). Table 2 shows the characteristics of the Letrozole treatment cycles where each patient had received one letrozole treatment cycle. The number of days between completion of treatment with Letrozole and DISCUSSION A simple, inexpensive and safe alternative to CC that can cover the goal of ovulation induction to induce monofollicular development and subsequent ovulation is needed. In this study, the mean (±SD) day of HCG administration was 13.2±1.76 and this agrees with the results of Mitwally and Casper, as it was 14.2±2.1 (1). In this study, the mean (±SD) number of days between completion of treatment with Letrozole and the day of HCG administration was 6.2±1.8 days. Letrozole has a short half-life (around 2 days) Vol. 9, No. 2, 2004 Elnashar et al. Letrozole for CC-resistant PCOS patients 159
4 Table 3. Clinical characteristics of both Letrozole responders and Letrozole non-responders. Variable Responders (n=24) Non-Responders (n=20) Significance 1-Age(years) 26.7± ±4.36 NS (a) 2-Period of infertility(y) 4.56± ±2.29 NS (a) 3-BMI (kgm/m2) 30.07± ±3.59 NS (a) 4-Waist (cm) 99± ±8.41 Ns (a) 5-W/H ratio 0.89± ±0.04 NS (a) 6-Menstrual pattern: Oligomenorrhea: No(%) 16 (66.66%) 14 (70%) NS (b) Amenorrhea: No (%) 8 (33.33%) 6 (30%) NS (b) 7-Hirsutism: No(%) 15 (62.5%) 13 (65%) NS (b) 6-LH (IU/ml) 16.7± ±3.65 NS (a) 7-FSH (IU/ml) 6.5± ±1.81 NS (a) 8-LH/FSH ratio 2.68± ±0.45 NS (a) NS= not significant. Variables are measured by mean ±SD P value = 0.05 (a) t test (b) X 2 tests leading to lower negligible levels of Letrozole in the body around the time of ovulation and early embryogenesis period (5). Letrozole was very well tolerated as no patients complained of any side effects. Because of the tolerability of Letrozole and its short half-life, Letrozole has been used as a single dose of 20mg on the third day of the menstrual cycle to ensure low levels around the time of ovulation without any side effects (9). In this study, the mean number of mature follicles 18 mm on the day of HCG administration was 1.21 (range 1-2) where 19 patients (79%) developed one mature follicle and 5 patients (21%) developed 2 mature follicles. This limited number of mature follicles (range 1-2) with Letrozole will decrease the risk of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS). These results are in agreement with the results of Al-Omari et al (10) and Mitwally and Casper (5) Therefore, Letrozole treatment does not need intensive monitoring compared to CC and gonadotropins. In this study, the mean endometrial thickness on the day of HCG administration was 10.2±1.31 mm. Thus the endometrium was of adequate thickness to allow implantation. Letrozole induces ovulation but without estrogen receptors downregulation. The adverse endometrial effect seen with CC, which is augmented by the relatively long half-life of CC (5 days), are not seen with Letrozole. This result is consistent with the results of other studies; in this study, the mean cervical mucus score was 11.42±2.48 according to the criteria of Moghissi (8). He considered a cervical mucus score of > 10 is a good one while a score of <10 is a poor one. This result indicates that, Letrozole has no adverse antiestrogenic effect on the cervical mucus. This result is consistent with the results of Metawie (11) Poor mucus at midcycle can be a physical barrier that decreases sperm penetration. In this study, ovulation occurred in 24 cases (54.6%). Administration of Letrozole in the early part of the menstrual cycle, would release the pituitary/hypothalamic axis from the estrogenic negative feedback, similar to the effect of CC but without estrogen receptors down-regulation, and the resulting increase in gonadotropin secretion could stimulate ovarian follicle development (1). Also, Letrozole may act locally in the ovary to increase the follicular sensitivity to FSH by increasing the local androgen in the ovary because conversion of androgen substrate to estrogen is blocked. The ovulation rate in this study is lower than that obtained by other studies using Letrozole in ovulation induction. Mitwally and Casper (5) had ovulatory rates of 75%, Al-Omari et al (10) had an ovulatory rate of 87.5% and Metawie (11) had a 160 Elnashar et al. Letrozole for CC-resistant PCOS patients MEFSJ
5 rate of 92.5%. However, the variable results can be explained by the smaller numbers of the patients of other studies; in our study, we administered Letrozole for only one cycle (i.e. ovulatory rate per cycle), while the 22 patients in Al-Omari study received Letrozole for 32 treatment cycles from the second day of the menstrual cycle (10). Metawie started Letrozole in a dose of 5mg/day for 5 days (11). In this study, pregnancy occurred in 6 patients; thus the percent of pregnancies per induced ovulatory cycle is 25%. This result is comparable with the results of Mitwally and Casper (25%), Al- Omari et al (27.27%) and Metawie (17.5%) (5,10,11). All these pregnancies were single, which is consistent with the results of other studies. This may be due to the limited number of mature follicles (range 1-2). Compared to other methods of ovulation induction, the multiple pregnancy rate is approximately 10% with CC, almost entirely twins (12), about 15-25% with gonadotropins (13) and about 2 % with laparoscopic ovarian drilling (14). Compared to laparoscopic ovarian drilling, there is no risk of operative interference as the anesthetic risk, adhesion formation and the possibility of ovarian destruction and premature ovarian failure (15). Comparing both groups of Letrozole responders and non-responders as regards clinical and laboratory characteristics we found that, there were no significant differences as regards BMI, waist circumference and W/H ratio, hirsutism, LH, FSH and LH/FSH ratio. Thus we can give Letrozole to all patients with CC-resistance, as its efficacy is not limited to a specific abnormality. So it can be used whatever the BMI. Achieving weight reduction is extremely difficult, particularly as the metabolic status of patients with PCOS conspires against weight loss (16). Also, Letrozole can be used with good results in patients with hirsutism and there is no need to add dexamethasone to reduce adrenal androgen production. Dexamethasone can worsen diabetic tendencies because of its effect on blood sugar and as a result, it may not be a suitable treatment for patients with diabetes, insulin resistant or glucose intolerance, conditions present in many PCOS patients (3). Also from these results, Letrozole can be used in case of high LH without the need to add oral contraceptives for pretreatment suppression of LH. Oral contraceptive pills exacerbate insulin resistance and since many patients are overweight and obesity is a relative contraindication, this treatment may be unsuitable (17). Also, there is a doubt about the short and long term safety of ovarian suppression in polycystic ovary with oral contraceptives (18). In conclusion; induction of ovulation with Letrozole in CC-failure PCOS is associated with limited number of mature follicles, no adverse effect on endometrium or cervix, ovulation and pregnancy in a significant number of patients. Induction with Letrozole is not dependent on age, period of infertility, BMI, waist circumference, LH, FSH or LH/FSH ratio. Further studies are necessary to confirm our results. REFERENCES 1. Lidor AL, Goldenberg M, Cohen SB, Seidman DS, Mashiach S, Rabinovici J. Management of women with polycystic ovary syndrome who experienced premature luteinization during clomiphene citrate treatment. Fertil Steril 2000;74: Yen SS. chronic anovulation caused by peripheral endocrine disorders. In: Yen SS, Jaffe RB, eds. Reproductive endocrinology: physiology, pathophysiology, and clinical management, 3rd ed Philadelphia: Saunders:1991: Speroff L, Glass RH, Kase NG. Hormone biosynthesis, metabolism, and mechanism of action. In: Clinical gynecologic endocrinology and infertility. Baltimore, Lippincott, Williams & Wilkins, 6th Ed, 1999,31-105; ; Branigan ME, Estes A. Using oral contraceptives as a treatment for clomid-resistant patients. Fertil Steril 1999;71: Mitwally FM and Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75: Femara (Letrozole) package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5: Moghissi KS. Postcoital test, physiologic basis, technique and interpretation. Fertil Steril 1976;27: Mitwally MF, Casper RF. Single dose administration of the aromatase inhibitor, Letrozole: a simple and convenient effective method of ovulation induction. Fertil Steril 2001;76:S94-5. Vol. 9, No. 2, 2004 Elnashar et al. Letrozole for CC-resistant PCOS patients 161
6 10. Al-Omari W, Al-Hadithi N, Izat B, Sulaiman W. The effect of an aromatase inhibitor on ovulation induction and endometrial receptivity in clomiphene resistant women with polycystic ovary syndrome. Mid East Fertil Soc J 2001;6:S Metawie MH. Comparative study of aromatase inhibitor, Letrozole, with clomiphene citrate for induction of ovulation. Mid East Fertil Soc J 2001;6:S Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997;3: March CM. Human menopausal gonadotropins. Infertil Reprod Med Clin North Am 1990;1: Felemban A, Tan SL, Tulandi T. Laparoscopic treatment of polycystic ovary syndrome with insulated needle cautery, a reappraisal. Fertil Steril 2000:73: Balen AH, Jacobs HS. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil Steril 1994;62: Kim LH, Taylor AE, Barbieri RL. Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril 2000:73; Sheu WH, Hsu CH, Chen YS, Jeng CY, Fuh MM. Prospective evaluation of insulin resistance and lipid metabolism in women receiving the oral contraceptive. Clin Endocrinol 1994;40: Nader S, Riad-Gabriel M, Saad M. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997;82: Received on December 14, 2003; revised and accepted on March 1, Elnashar et al. Letrozole for CC-resistant PCOS patients MEFSJ
POLYCYSTIC OVARY SYNDROME
POLYCYSTIC OVARY SYNDROME Information Leaflet Your Health. Our Priority. Page 2 of 6 What is polycystic ovary syndrome? (PCOS) Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women
More informationHEALTH UPDATE. Polycystic Ovary Syndrome (PCOS)
HEALTH UPDATE PO Box 800760 Charlottesville, VA 22908 Gynecology: (434) 924-2773 Polycystic Ovary Syndrome (PCOS) What is it? An endocrine (hormonal) disorder. Because there is such variability in how
More informationINFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS)
Introduction Infertility is defined as the absence of pregnancy following 12 months of unprotected intercourse. Infertility may be caused by Ovulatory Dysfunction, Blocked Fallopian Tubes, Male Factor
More informationPolycystic Ovarian Syndrome
Polycystic Ovarian Syndrome What is Polycystic Ovarian Syndrome? Polycystic ovary syndrome (or PCOS) is a common condition affecting 3 to 5% of women of reproductive age. It is linked with hormonal imbalances,
More informationEmmett F. Branigan, MD,* Antoinette Estes, BS, Kenneth Walker, BS, Jillian Rothgeb, BS. Bellingham IVF and Infertility Center, Bellingham, WA
American Journal of Obstetrics and Gynecology (2006) 194, 1696 701 www.ajog.org Thorough sonographic oocyte retrieval during in vitro fertilization produces results similar to ovarian wedge resection in
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationMedications for Inducing Ovulation
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Medications for Inducing Ovulation A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction
More informationFACT SHEET. The Polycystic Ovary Syndrome (PCOS) Introduction
FACT SHEET The Polycystic Ovary Syndrome (PCOS) Introduction The polycystic ovary syndrome (PCOS) is the commonest hormonal disturbance to affect women. The main problems that women with PCOS experience
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Polycystic ovary syndrome (PCOS) is a disorder that affects as many as 5 10% of women. PCOS has three key features: 1) high levels of hormones called androgens; 2) irregular menstrual
More informationDrug Therapy Guidelines: Injectable Fertility Medications
Drug Therapy Guidelines: Injectable Fertility Medications Effective Date: 11/20/07 Committee Review Date: 7/12/00, 5/8/01, 1/15/02, 5/6/0, 12/16/0, 6/8/04, 12/16/05, 2/1/06, 10/15/06, 7/20/07, 11/5/07
More informationAnatomy and Physiology of Human Reproduction. Module 10a
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationFrom Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College
From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels Christine Day, RN, MS, CNS-BC Lake Superior College Overview Will review hormonal changes over the female lifespan Discuss the effects
More informationPolycystic Ovarian Syndrome (PCOS)
UW MEDICINE PATIENT EDUCATION Polycystic Ovarian Syndrome (PCOS) Signs, symptoms, and treatments What is PCOS? Polycystic ovarian syndrome (PCOS) is a disorder that affects up to 1 in 10 women of reproductive
More informationPolycystic ovary syndrome (PCOS)
Centre for Diabetes and Endocrinology - Patient information Polycystic ovary syndrome (PCOS) Approximately 1 in 5 women have polycystic ovaries. This describes the appearance of the ovaries when they are
More informationSaudi Med J 2007; Vol. 28 (7): 1039-1043
Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome Khalifa E. Sharquie, MD, PhD,
More informationEFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY
1 Nada Polyclinic, Po ega, Croatia 2 School of Medicine, University of Zagreb, Zagreb, Croatia Preliminary Communication Received: April 15, 2004 Accepted: June 16, 2004 EFFECT OF INCREASED TESTOSTERONE
More informationMedications for Inducing Ovulation
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Medications for Inducing Ovulation A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction
More informationWelcome to chapter 8. The following chapter is called "Monitoring IVF Cycle & Oocyte Retrieval". The author is Professor Jie Qiao.
Welcome to chapter 8. The following chapter is called "Monitoring IVF Cycle & Oocyte Retrieval". The author is Professor Jie Qiao. The learning objectives of this chapter are 2 fold. The first section
More informationSubject Index. Bariatric surgery, obesity management 134
Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,
More informationThe Menstrual Cycle. Model 1: Ovarian Cycle follicular cells
The Menstrual Cycle REVIEW questions to complete before starting this POGIL activity 1. Gonads produce both gametes and sex steroid hormones. For the female, name the: A. gonads ovaries B. gametes oocyte/ovum/egg
More informationCYCLE EVALUATION. Please review this guide carefully. I. Early In Cycle. A. Selection of the Dominant Follicle (~ Day 3)
CYCLE EVALUATION In order to evaluate how well you ovulate, we will see you on three days during your menstrual cycle. Early in the cycle you select a dominant follicle, on or about the third day of your
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationPolycystic ovary syndrome: what it means for your long-term health
Polycystic ovary syndrome: what it means for your long-term health Information for you Published in February 2005, minor amendments in June 2005 Revised 2009 What is polycystic ovary syndrome? Polycystic
More informationResearch Article Association of ABO Blood Type and Ovarian Stimulation Response in Oocyte Donors
Cronicon OPEN ACCESS Nigel Pereira 1 *, Anne P Hutchinson 2, Jovana P Lekovich 1, Rony T Elias 1, Zev Rosenwaks 1 and Steven D Spandorfer 1 1 Ronald O Perelman and Claudia Cohen Center for Reproductive
More informationEastern Mediterranean Health Journal, Vol. 10, No. 3, 2004 437
Eastern Mediterranean Health Journal, Vol. 10, No. 3, 2004 437 Report Normal uterine size in women of reproductive age in northern Islamic Republic of Iran S. Esmaelzadeh, 1 N. Rezaei 1 and M. HajiAhmadi
More informationElevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome
Human Reproduction vol.14 no.3 pp.601 605, 1999 Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome Nicola Doldi
More informationHow do fertility drugs work?
How do fertility drugs work? Under normal circumstances, ovulation occurs once a month when a ripened egg which is ready to be fertilised is released from the ovaries. For couples who are trying to conceive,
More informationAbigail R. Proffer, M.D. October 4, 2013
Abigail R. Proffer, M.D. October 4, 2013 Topics Human Papillomavirus (HPV) Vaccines Pap smears Colposcopy Contraception Polycystic Ovary Syndrome (PCOS) Can I get pregnant? Miscarriage Abnormal Uterine
More informationClinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries
International Endocrinology Volume 2012, Article ID 492803, 6 pages doi:10.1155/2012/492803 Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory
More informationThe objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand
1 The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand the factors affecting the choice of protocol based
More informationHormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and
Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her
More informationIn Vitro Fertilization
Patient Education In Vitro Fertilization What to expect This handout describes how to prepare for and what to expect when you have in vitro fertilization. It provides written information about this process,
More informationHull & East Riding Prescribing Committee
Hull & East Riding Prescribing Committee Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis or prior to Endometrial Ablation, or
More informationGeorgia Reproductive Specialists
Georgia Reproductive Specialists A cost efficient approach to infertility diagnosis and Treatment for the OBGYN generalist Introduction The purpose of this proposal is to outline suggested clinical pathways
More informationThe IUI procedure Who should consider an IUI IUI success rates IUI cost What to consider if IUI is unsuccessful. The IUI procedure:
A Complete Guide to understanding IUI (intrauterine insemination) and artificial insemination (Eric Daiter, MD Board Certified in Reproductive Endocrinology and Infertility) The IUI procedure Who should
More informationwomen and sport Fertility Angelica Lindén Hirschberg
women and sport SCIENTIFIC REPORT SERIESI issue 2.5 YEAR 2014 Fertility Angelica Lindén Hirschberg PUBLISHED BY SISU sport books IN COOPERATION WITH WORLD VILLAGE OF WOMAN SPORTS FERTILITY Angelica Lindén
More informationPolycystic Ovarian Disease: Treatment Protocols
October 08, 2011 By Galal Lotfi, MD, MRCOG [1] Stein and Leventhal were the first to recognize an association between the presence of polycystic ovaries and signs of hirsutism, amenorrhea, oligomenorrhea
More informationThe Menstrual Cycle, Hormones and Fertility Treatment
The Menstrual Cycle, Hormones and Fertility Treatment How many of us understand how our monthly cycle works? Every 28 days (or thereabouts), between the ages of around 13 and 51, a woman will release a
More informationArtificial insemination with donor sperm
Artificial insemination with donor sperm Ref. 123 / 2009 Reproductive Medicine Unit Servicio de Medicina de la Reproducción Gran Vía Carlos III 71-75 08028 Barcelona Tel. (+34) 93 227 47 00 Fax. (+34)
More informationIntroduction Ovarian cysts are a very common female condition. An ovarian cyst is a fluid-filled sac on an ovary in the female reproductive system.
Ovarian Cysts Introduction Ovarian cysts are a very common female condition. An ovarian cyst is a fluid-filled sac on an ovary in the female reproductive system. Most women have ovarian cysts sometime
More informationArtificial insemination
Artificial insemination What is involved? Artificial insemination is an assisted reproduction technique that consists of inserting laboratory-treated spermatozoa into the woman s uterus or cervical canal.
More informationThe effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome
Middle East Fertility Society Journal Vol. 12, No. 3, 2007 Copyright Middle East Fertility Society The effect of administration of metformin on lipid profile changes and insulin resistance in patients
More informationReduced Ovarian Reserve Is there any hope for a bad egg?
Reduced Ovarian Reserve Is there any hope for a bad egg? Dr. Phil Boyle Galway Clinic, 19 th March 2014 For more information on Low AMH see www.napro.ie Anti Mullerian Hormone AMH levels are commonly measured
More informationHirsutism and Polycystic Ovary Syndrome (PCOS)
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under
More informationEhlers-Danlos Syndrome Fertility Issues. Objectives
Ehlers-Danlos Syndrome Fertility Issues Baltimore Inner Harbor Independence Day Brad Hurst, M.D. Professor Reproductive Endocrinology Carolinas Medical Center - Charlotte, North Carolina Objectives Determine
More informationThe Journal of Integrated Health Sciences
JIHS Available online at www.jihs.in The Journal of Integrated Health Sciences A study of endocrine profile in premenopausal women with hirsutism Lakhani Som J 1*, Lakhani Om J 2, Raval RC 3 1 Assistant
More informationPage 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome
Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome I. LANE WONG, MD, FACOG. www.hopeivf.com www.hopefertilitycenter.com Polycystic Ovary Syndrome (PCOS), Insulin
More informationIn vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval
In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval David E. Reichman, M.D., Anate Aelion Brauer, M.D., Dan Goldschlag,
More informationEgg Donation Process, Risks, Consent and Agreement
THE CENTER FOR HUMAN REPRODUCTION (CHR) 21 East 69 th Street, New York, NY 10021 T: 212-994-4400; F: 212-994-4499 Egg Donation Process, Risks, Consent and Agreement Updated on: 10/8/2014 Date: Egg Donor
More informationTHE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT FOR IN VITRO FERTILIZATION AND EMBRYO TRANSFER
THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT FOR IN VITRO FERTILIZATION AND EMBRYO TRANSFER Partner #1 Last Name (Surname): Partner #1 First Name: Partner #1 Last 5 Digits
More informationGuidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version)
Guidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version) 1. Scope This laboratory Guideline is intended to assist community
More informationPage 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome
Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome I. LANE WONG, MD, FACOG. www.hopeivf.com Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), Type
More informationOvarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002
Case Reports 21 August 2002 Ovarian Cyst Homoeopathy Clinic Check Yourself If you have any of the following symptoms call your doctor. Sense of fullness or pressure or a dull ache in the abdomen Pain during
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ACEGON, 50 microgram/ml, solution for injection for cattle. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active
More information1: Chlamydia. Infertility National Public Awareness Campaign. Information Sheet. Female Infertility. What is Chlamydia?
Infertility National Public Awareness Campaign Information Sheet Female Infertility 1: Chlamydia What is Chlamydia? Genital Chlamydia is a bacterium infecting the genital tract, eyes, and throat. It is
More informationDiagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro
Legro BMC Medicine (2015) 13:64 DOI 10.1186/s12916-015-0299-2 QUESTION AND ANSWER Diagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro Richard Legro Open Access
More informationInsulin Resistance and PCOS: A not uncommon reproductive disorder
Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses
More informationOVULATION & INTRAUTERINE INSEMINATION (IUI)
OVULATION & This handbook is intended to give you an overview of infertility treatment with IUI and ovulation induction and to better understand the medical circumstances that lead to this treatment option.
More informationUnit 3 REPRODUCTIVE SYSTEMS AND THE MENSTRUAL CYCLE
Unit 3 REPRODUCTIVE SYSTEMS AND THE MENSTRUAL CYCLE Learning Objectives By the end of this unit, the learner should be able to: Explain the importance of understanding the male and female reproductive
More informationpatientinformation Polycystic ovary syndrome Obstetrics & Gynaecology The Rotherham NHS Foundation Trust
The Rotherham NHS Foundation Trust Polycystic ovary syndrome Obstetrics & Gynaecology patientinformation Your health, your life, your choice, our passion Hearing about your experience of our services is
More informationDysfunctional Uterine Bleeding
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Dysfunctional Uterine Bleeding Michele Tartaglia, DO Michele Tartaglia, DO, FACOOG, CS Assistant Professor and Residency Program Director
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationPCOS. What to do about insulin resistance in. Aclearer understanding of. In this article: By R. Hugh Gorwill, MD, FRCSC
Focus on CME at Queen s University Queen s University What to do about insulin resistance in PCOS By R. Hugh Gorwill, MD, FRCSC In this article: Aclearer understanding of polycystic ovary syndrome (PCOS)
More information1. AMOUNT OF FSH PRESENT
The Menstrual Cycle Name Date Period PRE-LAB 1. Write down three facts you know about the menstrual cycle. A. B. C. FOLLICULAR PHASE Within the ovaries are located many egg cells. Each egg is enclosed
More informationThe ABC s and T s of Male Infertility
The ABC s and T s of Male Infertility Men s Health Initiative of BC - Focus on Testosterone Ethan D. Grober, MD, MEd, FRCSC Assistant Professor University of Toronto Department of Surgery, Division of
More informationPOLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS
POLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS I. Lane Wong, M.D., F.A.C.O.G. Board Certified, Reproductive Endocrinology and Infertility Recently, there has
More informationIn - Vitro Fertilization Handbook
In - Vitro Fertilization Handbook William F. Ziegler, D.O. Medical Director Scott Kratka, ELD, TS Embryology Laboratory Director Lauren F. Lucas, P.A.-C, M.S. Physician Assistant Frances Cerniak, R.N.
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Fertility care for women diagnosed with cancer Information For Patients INF/DRM/NUR/16 V1/01/11/2013 1 2 Contents Page Overview 4 Our Service 4
More informationACTIVITY DISCLAIMER. Polycystic Ovary Syndrome and Hyperandrogenism
Polycystic Ovary Syndrome and Hyperandrogenism Lisa G. Soldat, MD, MS, FAAFP ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family Physicians for educational
More informationPACKAGE INSERT PREGNYL. (chorionic gonadotropin for injection, USP) 10,000 units/vial. Human Gonadotropin
PACKAGE INSERT PREGNYL (chorionic gonadotropin for injection, USP) 10,000 units/vial Human Gonadotropin Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 Date of Revision: February
More informationMetformin treatment before IVF / ICSI in non obese PCOS women
Metformin treatment before IVF / ICSI in non obese PCOS women A Nordic, prospective, randomised, double blind, multicentre study Sigrun Kjøtrød University Hospital of Trondheim, Norway Metformin effects
More informationAbnormal Uterine Bleeding FAQ Sheet
Abnormal Uterine Bleeding FAQ Sheet What is abnormal uterine bleeding? Under normal circumstances, a woman's uterus sheds a limited amount of blood during each menstrual period. Bleeding that occurs between
More informationStrategies and the Nursing Care Management of Adolescents Diagnosed with PCOS. Conflicts of Interest. Objectives. None Phaedra Thomas 4/23/2015
Strategies and the Nursing Care Management of Adolescents Diagnosed with PCOS Phaedra Thomas, RN BSN Co-Director and Nurse Educator Center for Young Women s Health Boston Children s Hospital youngwomenshealth.org
More informationClinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve
International Reproductive Medicine, Article ID 581451, 5 pages http://dx.doi.org/10.1155/2014/581451 Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for
More informationWOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Endometriosis
Endometriosis WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 The lining of the uterus is called the endometrium. Sometimes, endometrial tissue grows elsewhere in the body. When this happens
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationPolycystic Ovary Syndrome: Diagnosis and Treatment
The American Journal of Medicine (2007) 120, 128-132 UPDATE IN OFFICE MANAGEMENT Polycystic Ovary Syndrome: Diagnosis and Treatment Tracy L. Setji, MD, Ann J. Brown, MD, MHS Department of Medicine, Division
More informationThe causes of infertility include abnormalities of any portion of the male or female reproductive system.
Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz IN SUMMARY Defined as 1 year of unprotected intercourse during which
More informationFertility Preservation in Women with Cancer. Objectives. Patient #1 10/24/2011. The audience will understand: How cancer therapy affects fertility.
Fertility Preservation in Women with Cancer Leslie R. DeMars Dartmouth-Hitchcock Medical Center Objectives The audience will understand: How cancer therapy affects fertility. Who should be considered for
More informationAge and Fertility. A Guide for Patients PATIENT INFORMATION SERIES
Age and Fertility A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications
More informationThe Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness
Bulletin of the Osaka Medical College 49 1, 2 5-9, 2003 5 Original Article The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness Yoshiki YAMASHITA, Toshimitsu
More informationImprovement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome
65 ORIGINAL Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome Hirobumi Niki, Toshiya Matsuzaki, Riyo Kinouchi, Takeshi
More informationAcupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection
Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Sandra L. Emmons, MD Phillip Patton, MD Source: Medical Acupuncture, A Journal For Physicians By Physicians Spring
More informationHOW IS OVARIAN RESERVE ASSESSED?
HOW IS OVARIAN RESERVE ASSESSED? The majority of indicators we have to assess OR assess egg quantity rather than egg quality and these two do not always go hand in hand. No individual test is a perfect
More informationBody Mass Index and Gonadotropin Hormones (LH & FSH) Associate With Clinical Symptoms Among Women With Polycystic Ovary Syndrome
Global Journal of Health Science; Vol. 7, No. 2; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Body Mass Index and Gonadotropin Hormones (LH & FSH) Associate
More informationAbnormal Uterine Bleeding: Simple evaluation and management in premenopausal women
Objectives Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Provide a framework to evaluate abnormal uterine bleeding (AUB) Review medical and surgical management options
More informationSPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE
SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE David Kreiner, M. D. * Kathleen Droesch, M.D. Daniel Navot, M.D. Richard Scott, M.D. Zev Rosenwaks, M.D.
More informationSystematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc., M.D.
Role of luteinizing hormone supplementation in the follicular phase and pregnancy, during controlled ovarian hyperstimulation in in vitro fertilization Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc.,
More informationOVARIAN CYSTS. Types of Ovarian Cysts There are many types of ovarian cysts and these can be categorized into functional and nonfunctional
OVARIAN CYSTS Follicular Cyst Ovarian cysts are fluid-filled sacs that form within or on the ovary. The majority of these cysts are functional meaning they usually form during a normal menstrual cycle.
More informationFERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile?
FERTILITY AND AGE Introduction Delaying pregnancy is a common choice for women in today's society. The number of women in their late 30s and 40s attempting pregnancy and having babies has increased in
More informationDirector, IVF Program, Division of Reproductive Endocrinology & Infertility
Director, IVF Program, Division of Reproductive Endocrinology & Infertility Date: January 17, 2006 To: From: RE: All IVF candidates Chief, Reproductive Endocrinology & Infertility Criteria for IVF program
More informationMECHANISM OF ACTION. Fertility Awareness-Based Methods. Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA
Fertility Awareness-Based Methods Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA Fertility awareness helps couples understand how to avoid pregnancy or how to become pregnant.
More informationManagement fertility sparing degli endometriomi Errico Zupi
Management fertility sparing degli endometriomi Errico Zupi Università Tor Vergata Roma Management of endometrioma Pain Infertility Surgical treatment Medical treatment Infertility clinic Both medical
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationThe PCOS - Diabetes Connection
PCOS Awareness Symposium 2015 Philadelphia Saturday, April 18 th, 2015 The PCOS - Diabetes Connection Preventing Stroke, Kidney Disease, Liver Disease & Other Complications Katherine Sherif, MD Professor
More informationPolycystic ovarian syndrome in women with acne
Original Article Polycystic ovarian syndrome in women with acne Sayera Begum*, M Zakir Hossain**, Md. Fashiur Rahman, Laila Anjuman Banu *Department of Dermatology & Venereology, Central Police Hospital,
More informationGP tool. Polycystic ovary syndrome
Polycystic ovary syndrome GP tool This resource is informed by the evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS), authored by the PCOS Australian Alliance
More informationFast Track to IVF. Objectives
Disclosure statement: Richard H. Reindollar, M.D. has no relevant financial relationships with any manufacturers of pharmaceuticals, laboratory supplies, or medical devices. Fast Track to IVF Richard H.
More informationOVARIAN CYSTS AND TORSION
Key: = important notes = reference to torsion = reference to malignancy OVARIAN CYSTS AND TORSION Epidemiology:
More informationAbnormal Uterine Bleeding
Abnormal Uterine Bleeding WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Abnormal uterine bleeding is one of the most common reasons women see their doctors. It can occur at any age and has
More information